Literature DB >> 497315

The return to sleep.

M H Bonnet, W B Webb.   

Abstract

Six young adult subjects were awakened five to eight times per night from stage 2 sleep in a standardized manner for a series of at least 11 non-consecutive nights. After adaptation to the procedure, subjects received placebo, pentobarbital, or flurazepam on two random nights and caffeine on one night. The latency of the return to sleep after each awakening was measured. On placebo nights a characteristic U-shaped curve of latency as a function of time of night was found. Latencies were long shortly after sleep onset but decreased rapidly to about 50 sec before beginning an approximately linear logarithmic increase throughout the rest of the night. The drugs characteristically altered this time course. Pentobarbital decreased latencies in the first half of the night. Flurazepam decreased latencies throughout the night. Caffeine increased latencies during the first half of the night.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 497315     DOI: 10.1016/0301-0511(79)90050-4

Source DB:  PubMed          Journal:  Biol Psychol        ISSN: 0301-0511            Impact factor:   3.251


  4 in total

Review 1.  Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.

Authors:  Christopher J Edgar; Edward F Pace-Schott; Keith A Wesnes
Journal:  Hum Psychopharmacol       Date:  2009-07       Impact factor: 1.672

2.  Sleep studies in clinical pharmacology.

Authors:  I Oswald
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

3.  Examining initial sleep onset in primary insomnia: a case-control study using 4-second epochs.

Authors:  Douglas E Moul; Anne Germain; J David Cashmere; Michael Quigley; Jean M Miewald; Daniel J Buysse
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

4.  Genetic variants in RBFOX3 are associated with sleep latency.

Authors:  Najaf Amin; Karla V Allebrandt; Ashley van der Spek; Bertram Müller-Myhsok; Karin Hek; Maris Teder-Laving; Caroline Hayward; Tõnu Esko; Josine G van Mill; Hamdi Mbarek; Nathaniel F Watson; Scott A Melville; Fabiola M Del Greco; Enda M Byrne; Edwin Oole; Ivana Kolcic; Ting-Hsu Chen; Daniel S Evans; Josef Coresh; Nicole Vogelzangs; Juha Karjalainen; Gonneke Willemsen; Sina A Gharib; Lina Zgaga; Evelin Mihailov; Katie L Stone; Harry Campbell; Rutger Ww Brouwer; Ayse Demirkan; Aaron Isaacs; Zoran Dogas; Kristin D Marciante; Susan Campbell; Fran Borovecki; Annemarie I Luik; Man Li; Jouke Jan Hottenga; Jennifer E Huffman; Mirjam Cgn van den Hout; Steven R Cummings; Yurii S Aulchenko; Philip R Gehrman; André G Uitterlinden; Heinz-Erich Wichmann; Martina Müller-Nurasyid; Rudolf Sn Fehrmann; Grant W Montgomery; Albert Hofman; Wen Hong Linda Kao; Ben A Oostra; Alan F Wright; Jacqueline M Vink; James F Wilson; Peter P Pramstaller; Andrew A Hicks; Ozren Polasek; Naresh M Punjabi; Susan Redline; Bruce M Psaty; Andrew C Heath; Martha Merrow; Gregory J Tranah; Daniel J Gottlieb; Dorret I Boomsma; Nicholas G Martin; Igor Rudan; Henning Tiemeier; Wilfred Fj van IJcken; Brenda W Penninx; Andres Metspalu; Thomas Meitinger; Lude Franke; Till Roenneberg; Cornelia M van Duijn
Journal:  Eur J Hum Genet       Date:  2016-05-04       Impact factor: 4.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.